An interventional study of Repetitive Transcranial Magnetic Stimulation (rTMS) in Depression and Anxiety, sponsored by Medical University of South Carolina. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-02.
Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Depression by Medical University of South Carolina — 17 open to participants now, 21 under way, none of them phase 3. Depression · Medical University of South Carolina.
Among the 47 studies in Depression by Medical University of South Carolina, this one is the 17th largest by planned enrollment of the 45 interventional ones that give a count, is one of 4 that started in 2021, is one of 31 with no phase, reaches primary completion later than 3 of the 20 other live ones, and was the 25th registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →17 of the 47 studies in Depression by Medical University of South Carolina are open now, in 1 country. Recruiting first, the newest first:
Medical University of South Carolina · Sites in United States
Ages 18–70
Medical University of South Carolina · Sites in United States
Ages 18+ · Healthy volunteers
Medical University of South Carolina · Sites in United States
Ages 18–80
Medical University of South Carolina · Sites in United States
Ages 18+
Medical University of South Carolina · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 10 · Phase 3 5 · Phase 4 3
First in 2005; this study’s year is marked. 4 started in 2021.
This study's planned enrollment of 70 is below the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 46 across the 45 interventional studies, 10 across the 2 observational. Of the 24 that completed or were terminated, 14 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
Medical University of South Carolina is the lead sponsor of 875 studies on the registry; 165 are open to participants now.
Of its 132 completed or terminated interventional studies of FDA-regulated products, 104 (79%) have results posted.
10 of the studies in Depression by Medical University of South Carolina that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04657432Medical University of South CarolinaBrief, High-dose rTMS for Depression | 2026-12-01 |
| NCT07226011Medical University of South CarolinaAccelerated High-Dose tDCS for Depression | 2026-12-28 |
| NCT07369557Medical University of South CarolinaMindfulness Training During Accelerated TMS for Depression | 2026-12-30 |
| NCT06748209Medical University of South CarolinaEstablishing Mobile Transcranial Magnetic Stimulation | 2027-03-01 |
| NCT05497115Medical University of South CarolinaTesting a Scalable Model of Care to Improve Patients Access to Mental Health Services After Traumatic Injury | 2027-03-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 47 studies in Depression by Medical University of South Carolina, from their registry updates:
This tab as a report to print or save as PDF → With an account.
High frequency repetitive transcranial magnetic stimulation (rTMS) has been shown to be safe, feasible, and acceptable. Conventionally, rTMS investigations have relied on rational decision trees for dosage determination. The purpose of this study is to systematically examine an accelerated protocol of intermittent theta burst (iTBS). Study 1 aims to provide a quantifiable dose-response curve for iTBS and depressive symptom reduction in major depression. Study 2 aims to determine the role of individual variations of their functional networks compared to the site of stimulation and clinical outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Clinically unstable medical disease:
Current or history of schizophrenia or other psychotic disorder, except psychosis not otherwise specified (NOS) when the presence of sensory hallucinations is clearly related to the subject's trauma, Bipolar Type I disorder, or dementia:
See further explanation under protection from risk.
Currently taking medications that have short half-lives, lower the seizure threshold, and do not have evidence of antidepressant efficacy. These include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
Device: Repetitive Transcranial Magnetic Stimulation (rTMS)
All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 2 is 10 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
Device: Repetitive Transcranial Magnetic Stimulation (rTMS)
All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 3 is 15 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
Device: Repetitive Transcranial Magnetic Stimulation (rTMS)
All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 4 is 20 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
Device: Repetitive Transcranial Magnetic Stimulation (rTMS)
All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 5 is 20 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
Device: Repetitive Transcranial Magnetic Stimulation (rTMS)
All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 6 is 25 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
Device: Repetitive Transcranial Magnetic Stimulation (rTMS)
All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 7 is 30 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
Device: Repetitive Transcranial Magnetic Stimulation (rTMS)
All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 8 is 35 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
Device: Repetitive Transcranial Magnetic Stimulation (rTMS)
All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 9 is 40 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
Device: Repetitive Transcranial Magnetic Stimulation (rTMS)
All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 10 is 40 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
Device: Repetitive Transcranial Magnetic Stimulation (rTMS)
All participants will be assigned to 10 sessions (per treatment day) of accelerated rTMS for 5 treatment days. All doses are active and within established therapeutic levels of rTMS. Dose 10 is 50 active sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
Device: Repetitive Transcranial Magnetic Stimulation (rTMS)
MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
Depression severity (change in score)
Depression severity as assessed by: 1\. Hamilton Scale for Depression (HAM-D) Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine are scored from 0-2. 10 - 13 mild; 14-17 mild to moderate; \>17 moderate to severe.
Time frame: Day 1, post-treatment point of 1 month
Depression severity (change in score)
Depression severity as assessed by: 2\. Montgomery-Asberg Depression Rating Scale (MADRS) Rating lies on the defined scale steps (0, 2, 4, 6) or between them (1, 3, 5). Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression.
Time frame: Day 1, post-treatment point of 1 month
Depression severity (change in score)
Depression severity as assessed by: 3\. Beck Depression Inventory-II (BDI-II) Rated on a 4-point scale ranging from 0 to 3 based on severity of each item. The maximum total score is 63.
Time frame: Day 1, post-treatment point of 1 month
Comorbid symptom severity, functional impairment, acceptability, and tolerability
Participants would complete various questionnaires (change in score assessed): 1\. Inventory of Depression and Anxious Symptoms (IDAS-II) -Questions are rated on a scale from 1-5 and covers a wide array of psychological measures
Time frame: Day 1, post-treatment point of 1 month
Comorbid symptom severity, functional impairment, acceptability, and tolerability
Participants would complete various questionnaires (change in score assessed): 2\. Mood and Anxiety Symptom Questionnaire -Questions designed to assess symptoms of general distress using a 5-point Likert scale ranging from 1"not at all" to 5 "extremely".
Time frame: Day 1, post-treatment point of 1 month
Comorbid symptom severity, functional impairment, acceptability, and tolerability
Participants would complete various questionnaires (change in score assessed): 3\. Penn State Worry Questionnaire -Questions are rated on a scale from: 1-Not at all typical of me to 5-Very typical of me. Possible range of scores is 16-80 with the algorithm of Total scores: 16-39 Low Worry, 40-59 Moderate Worry, and 60-80 High Worry
Time frame: Day 1, post-treatment point of 1 month
Comorbid symptom severity, functional impairment, acceptability, and tolerability
Participants would complete various questionnaires (change in score assessed): 4\. PTSD Checklist (PCL-5) The PCL-5 is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD. The PCL-5 has a variety of purposes, including: Monitoring symptom change during and after treatment Screening individuals for PTSD Making a provisional PTSD diagnosis -Questions are rated on a 5-point Likert scale (0 = "Not at all" to 4 = "Extremely")
Time frame: Day 1, post-treatment point of 1 month
Comorbid symptom severity, functional impairment, acceptability, and tolerability
Participants would complete various questionnaires (change in score assessed): 5\. Life Events Checklist (LEC-5) The Life Events Checklist for DSM-5 (LEC-5) is a self-report measure designed to screen for potentially traumatic events in a respondent's lifetime. The LEC-5 assesses exposure to 16 events known to potentially result in PTSD or distress and includes one additional item assessing any other extraordinarily stressful event not captured in the first 16 items. -Responses are as followed: Happened to me; Witnessed it; Learned about it; Part of my job; Not sure; Doesn't apply
Time frame: Day 1, post-treatment point of 1 month
Comorbid symptom severity, functional impairment, acceptability, and tolerability
Participants would complete various questionnaires (change in score assessed): 6\. Childhood Trauma Questionnaire -The Childhood Trauma Questionnaire is a brief survey of six early traumatic experiences (death, divorce, violence, sexual abuse, illness or other), and assesses individual's understanding of their childhood trauma.
Time frame: Day 1, post-treatment point of 1 month
Comorbid symptom severity, functional impairment, acceptability, and tolerability
Participants would complete various questionnaires (change in score assessed): 7\. Fagerstrom Test for Nicotine Dependence -Yes/no items are scored from 0 to 1 and multiple-choice items are scored from 0 to 3. The items are summed to yield a total score of 0-10. The higher the total Fagerström score, the more intense is the patient's physical dependence on nicotine.
Time frame: Day 1, post-treatment point of 1 month
Comorbid symptom severity, functional impairment, acceptability, and tolerability
Participants would complete various questionnaires (change in score assessed): 8\. Alcohol Use Disorders Identification Test (AUDIT) -The Alcohol Use Disorders Identification Test (AUDIT) is a 10-item screening tool developed by the World Health Organization (WHO) to assess alcohol consumption, drinking behaviors, and alcohol-related problems.
Time frame: Day 1, post-treatment point of 1 month
Comorbid symptom severity, functional impairment, acceptability, and tolerability
Participants would complete various questionnaires (change in score assessed): 9\. World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) -Questions are rated on a a 5 point scale (from 0-4) Likert scale
Time frame: Day 1, post-treatment point of 1 month
Comorbid symptom severity, functional impairment, acceptability, and tolerability
Participants would complete various questionnaires (change in score assessed): 10\. World Health Organization Quality of Life - Brief Form (WHOQOL-BF) -Questions are rated on a a 5 point scale (from 1-5) Likert scale
Time frame: Day 1, post-treatment point of 1 month
Comorbid symptom severity, functional impairment, acceptability, and tolerability
Participants would complete various questionnaires (change in score assessed): 11\. Illness Intrusive Rating Scale (IIRS) -Questions are rated on a a 7 point scale (from 1-7) Likert scale which is a measure of the psychosocial impact of chronic disease
Time frame: Day 1, post-treatment point of 1 month
Comorbid symptom severity, functional impairment, acceptability, and tolerability
Participants would complete various questionnaires (change in score assessed): 12\. Quality of Life and Enjoyment and Satisfaction Questionnaire -Short Form (Q-LES-Q-SF) -Questions are rated on a 5 point scale (from 1-5) Likert scale. The minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70.
Time frame: Day 1, post-treatment point of 1 month
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started May 2021 (actual). Primary completion is estimated for Dec 2026, 66 months after the start.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 66 months is above that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of South Carolina →